<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7049568\results\search\disease\results.xml">
  <result pre="(5′-PPP-NS1shRNA), designed using the conserved region of a number of" exact="influenza" post="viruses, not only prevented NS1 expression but also induced"/>
  <result pre="expression, resulting in an antiviral state leading to inhibition of" exact="influenza" post="virus replication in vitro. In addition, administration of 5′-PPP-NS1shRNA"/>
  <result pre="alone.1 Although vaccination is the most cost-effective preventive strategy against" exact="influenza" post="infections, antiviral agents, specifically neuraminidase inhibitors, are the drugs"/>
  <result pre="specifically neuraminidase inhibitors, are the drugs of choice to treat" exact="influenza" post="viral infections.2 To have the antiviral effects, oseltamivir, the"/>
  <result pre="a new drug, baloxavir marboxil, marketed as Xofluza, which inhibits" exact="influenza" post="viral polymerase, was approved to treat influenza infections, almost"/>
  <result pre="Xofluza, which inhibits influenza viral polymerase, was approved to treat" exact="influenza" post="infections, almost two decades after the approval of oseltamivir.3"/>
  <result pre="oseltamivir, Xofluza needs to be administered within 48 h of" exact="influenza" post="diagnosis. However, drug resistance has been a major issue"/>
  <result pre="retinoic acid-inducible gene-I (RIG-I) is a major pathogen sensor for" exact="influenza" post="virus, and its activation is inhibited by nonstructural protein"/>
  <result pre="its activation is inhibited by nonstructural protein 1 (NS1) of" exact="influenza" post="virus.17, 18, 19, 20 Short single-stranded RNAs (ssRNAs) containing"/>
  <result pre="confers protection against not only drug-sensitive and -resistant strains of" exact="influenza" post="independent of their hemagglutinin (HA) and neuraminidase (NA) type,"/>
  <result pre="1 IFN-sufficient population), and demonstrate that it is efficacious against" exact="influenza" post="virus infection in prophylactic and therapeutic settings, both in"/>
  <result pre="of 5′-PPP-NS1shRNA, which not only suppresses the NS1 gene of" exact="influenza" post="virus but also activates RIG-I-mediated antiviral responses by virtue"/>
  <result pre="sequence alignment of the NS gene segment of 12 different" exact="influenza" post="viruses. Sequence alignment results revealed nine short stretches of"/>
  <result pre="sequence that were the most conserved among the 12 different" exact="influenza" post="viruses and that served as the putative target (NS1)"/>
  <result pre="NS1 target sense sequence, stem loop, target antisense sequence, and" exact="hepatitis" post="delta virus (HDV) ribozyme (Figure 1B). The purpose of"/>
  <result pre="of RNA accessibility (mppRNA) analysis. Peaks indicate domains along the" exact="influenza" post="A/PR/8/34 sequence with a higher probability of access for"/>
  <result pre="domains with ≥97% homology with the consensus sequence of 12" exact="influenza" post="A strains. #1, #4, and #9 sequence domains from"/>
  <result pre="(in blue), loop (in green), target antisense (in gray), and" exact="hepatitis" post="delta virus (HDV) ribozyme (in pink). Both ends of"/>
  <result pre="cells were also infected with 1.0 MOI of A/Brisbane/59 (H1N1)" exact="influenza" post="virus and were harvested 24 h post-infection for mRNA"/>
  <result pre="and others have shown the antiviral potential of 5′-PPP-RNA for" exact="influenza" post="and other viruses.21, 22, 23,32,33 In this study, we"/>
  <result pre="antiviral responses and also knock down the NS1 protein of" exact="influenza" post="virus. In order to assess the functionality of our"/>
  <result pre="these dual-function NS1shRNAs to suppress production of NS1 by the" exact="influenza" post="virus. A549 cells were mock transfected or transfected with"/>
  <result pre="their m7G-capped counterparts, and 24 h later infected with A/Brisbane/9/2007" exact="influenza" post="virus. 80%–90% knockdown in NS1 mRNA levels was achieved"/>
  <result pre="in cells treated with NS1shRNA uncapped or m7G-capped followed by" exact="influenza" post="virus infection as compared with controls. However, no reduction"/>
  <result pre="support the hypothesis that NS1shRNA mediates antiviral effects both by" exact="suppression" post="of NS1 expression and by induction of type 1"/>
  <result pre="the transfected cells were infected with 1 MOI of A/Brisbane/59/2007" exact="influenza" post="virus. The cells were harvested 24 h post-infection for"/>
  <result pre="direct inhibition of NS1 by shRNA. RIG-I activation and NS1" exact="suppression" post="work synergistically in dual-functioning 5′-PPP-NS1shRNA. 5′-PPP-containing scrambled shRNA construct"/>
  <result pre="The transfected cells were infected with 1.0 MOI of A/Brisbane/59/2007" exact="influenza" post="virus at indicated time points (i.e., 6 [filled bars],"/>
  <result pre="A549 cells were first infected with 1.0 MOI of A/Brisbane/59/2007" exact="influenza" post="virus and at 6, 12, and 24 h post-infection,"/>
  <result pre="were mock infected or infected with 1.0 MOI of A/Brisbane/59" exact="influenza" post="virus, and 6 (filled bars), 12 (empty bars), or"/>
  <result pre="indicate that a single dose of 5′-PPP-shRNA results in NS1" exact="suppression" post="and RIG-I activation, and suppresses influenza viral replication significantly."/>
  <result pre="5′-PPP-shRNA results in NS1 suppression and RIG-I activation, and suppresses" exact="influenza" post="viral replication significantly. However, single-dose administration on the same"/>
  <result pre="groups and PBS group. Discussion Despite being a vaccine-preventable disease," exact="influenza" post="continues to remain a major public health problem worldwide."/>
  <result pre="291,000 and 646,000 influenza-associated deaths.35 In the United States alone," exact="influenza" post="viruses are estimated to infect more than 50 million"/>
  <result pre="and people with certain medical conditions, such as cancer, chronic" exact="lung disease," post="heart disease, diabetes, and blood, lung, or kidney disorders."/>
  <result pre="with certain medical conditions, such as cancer, chronic lung disease," exact="heart disease," post="diabetes, and blood, lung, or kidney disorders. Current influenza"/>
  <result pre="heart disease, diabetes, and blood, lung, or kidney disorders. Current" exact="influenza" post="vaccine formulations typically generate strain-specific immune responses and are"/>
  <result pre="year to match the circulating virus strains. The effectiveness of" exact="influenza" post="vaccines is largely dependent on the antigenic closeness of"/>
  <result pre="for unmatched strains. The overall vaccine effectiveness of the 2018–2019" exact="influenza" post="vaccine against both influenza A and B viruses is"/>
  <result pre="overall vaccine effectiveness of the 2018–2019 influenza vaccine against both" exact="influenza" post="A and B viruses is estimated to be 40%.1"/>
  <result pre="viruses is estimated to be 40%.1 However, the effectiveness of" exact="influenza" post="vaccines in young children and older adults is comparatively"/>
  <result pre="antiviral drugs play a central part in the treatment of" exact="influenza" post="viral infections. Three classes of drugs are licensed to"/>
  <result pre="its derivatives are no longer used because 100% of circulating" exact="influenza" post="viruses are resistant to them.37 The majority of circulating"/>
  <result pre="earlier that activating the RIG-I pathway inhibited the growth of" exact="influenza" post="viruses irrespective of their genetic makeup, drug sensitivity status,"/>
  <result pre="RIG-I activation. Using small interfering RNA against nucleoprotein (NPsiRNA) of" exact="influenza" post="virus, a reduction of 1–2 logs in viral titer"/>
  <result pre="and mouse-adapted A/Puerto Rico/8/34 (H1N1) viruses were obtained from the" exact="influenza" post="division Centers for Disease Control and Prevention (CDC) repository"/>
  <result pre="The sequences of the NS1 gene segment from 12 different" exact="influenza" post="A viruses were aligned using NCBI tblastn to find"/>
  <result pre="most effective in knocking down NS1 message and protein of" exact="influenza" post="viruses used in this study, and #4 was used"/>
  <result pre="12, or 24 h post-transfection, cells were infected with A/Brisbane/59/2007" exact="influenza" post="virus at an MOI of 1.0 with trypsin supplementation."/>
  <result pre="potential of 5′-PPP-NS1shRNA, A549 cells were first infected with A/Brisbane/59/2007" exact="influenza" post="virus at an MOI of 1.0 with trypsin supplementation"/>
  <result pre="manuscript. References References 1collab: Centers for Disease Control and PreventionEstimated" exact="influenza" post="illnesses, medical visits, hospitalizations, and deaths in the United"/>
  <result pre="illnesses, medical visits, hospitalizations, and deaths in the United States—2017–2018" exact="influenza" post="seasonhttps://www.cdc.gov/flu/about/burden/2017-2018.htm2018 2HaydenF.G.AtmarR.L.SchillingM.JohnsonC.PoretzD.PaarD.HusonL.WardP.MillsR.G.Use of the selective oral neuraminidase inhibitor oseltamivir"/>
  <result pre="First Global ApprovalDrugs78201869369729623652 4Influenza Project TeamOseltamivir resistance in human seasonal" exact="influenza" post="viruses (A/H1N1) in EU and EFTA countries: an updateEuro"/>
  <result pre="countries: an updateEuro Surveill.132008803218445425 5LackenbyA.HungnesO.DudmanS.G.MeijerA.PagetW.J.HayA.J.ZambonM.C.Emergence of resistance to oseltamivir among" exact="influenza" post="A(H1N1) viruses in EuropeEuro Surveill.132008802618445375 6HaugeS.H.DudmanS.BorgenK.LackenbyA.HungnesO.Oseltamivir-resistant influenza viruses A"/>
  <result pre="to oseltamivir among influenza A(H1N1) viruses in EuropeEuro Surveill.132008802618445375 6HaugeS.H.DudmanS.BorgenK.LackenbyA.HungnesO.Oseltamivir-resistant" exact="influenza" post="viruses A (H1N1), Norway, 2007-08Emerg. Infect. Dis.15200915516219193257 7MosconaA.Global transmission"/>
  <result pre="Engl. J. Med.360200995395619258250 8Okomo-AdhiamboM.FryA.M.SuS.NguyenH.T.ElalA.A.NegronE.HandJ.GartenR.J.BarnesJ.XiyanX.collab: 2013–14 US Influenza Antiviral Working GroupOseltamivir-resistant" exact="influenza" post="A(H1N1)pdm09 viruses, United States, 2013-14Emerg. Infect. Dis.21201513614125532050 9OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.CusackS.Characterization of"/>
  <result pre="influenza A(H1N1)pdm09 viruses, United States, 2013-14Emerg. Infect. Dis.21201513614125532050 9OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.CusackS.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
  <result pre="by treatment with the endonuclease inhibitor baloxavir marboxilSci. Rep.82018963329941893 10TandelK.SharmaS.DashP.K.ParidaM.Oseltamivir-resistant" exact="influenza" post="A(H1N1)pdm09 virus associated with high case fatality, India 2015J."/>
  <result pre="Next StepsJ. Infect. Dis.221202033733931309982 12GubarevaL.V.MishinV.P.PatelM.C.ChesnokovA.NguyenH.T.De La CruzJ.SpencerS.CampbellA.P.SinnerM.ReidH.Assessing baloxavir susceptibility of" exact="influenza" post="viruses circulating in the United States during the 2016/17"/>
  <result pre="baloxavir treatment, Japan, January 2019Euro Surveill.2420191900170 14WangN.X.ZhengJ.J.Computational studies of H5N1" exact="influenza" post="virus resistance to oseltamivirProtein Sci.18200970771519309695 15KisoM.Iwatsuki-HorimotoK.YamayoshiS.UrakiR.ItoM.NakajimaN.YamadaS.ImaiM.KawakamiE.TomitaY.Emergence of Oseltamivir-Resistant H7N9"/>
  <result pre="acid sensors in antiviral immunityTrends Mol. Med.15200935936819665430 17GuoZ.ChenL.M.ZengH.GomezJ.A.PlowdenJ.FujitaT.KatzJ.M.DonisR.O.SambharaS.NS1 protein of" exact="influenza" post="A virus inhibits the function of intracytoplasmic pathogen sensor,"/>
  <result pre="I-mediated induction of beta interferon by the NS1 protein of" exact="influenza" post="A virusJ. Virol.81200751452417079289 20OpitzB.RejaibiA.DauberB.EckhardJ.VinzingM.SchmeckB.HippenstielS.SuttorpN.WolffT.IFNbeta induction by influenza A virus"/>
  <result pre="NS1 protein of influenza A virusJ. Virol.81200751452417079289 20OpitzB.RejaibiA.DauberB.EckhardJ.VinzingM.SchmeckB.HippenstielS.SuttorpN.WolffT.IFNbeta induction by" exact="influenza" post="A virus is mediated by RIG-I which is regulated"/>
  <result pre="the viral NS1 proteinCell. Microbiol.9200793093817140406 21DavisW.G.BowzardJ.B.SharmaS.D.WiensM.E.RanjanP.GangappaS.StuchlikO.PohlJ.DonisR.O.KatzJ.M.The 3′ untranslated regions of" exact="influenza" post="genomic sequences are 5'PPP-independent ligands for RIG-IPLoS ONE72012e3266122438882 22RanjanP.JayashankarL.DeydeV.ZengH.DavisW.G.PearceM.B.BowzardJ.B.HoelscherM.A.Jeisy-ScottV.WiensM.E.5'PPP-RNA"/>
  <result pre="drug-resistant avian H5N1 as well as 1918 and 2009 pandemic" exact="influenza" post="virus replicationVirol. J.7201010220492658 23SpiropoulouC.F.RanjanP.PearceM.B.SealyT.K.AlbariñoC.G.GangappaS.FujitaT.RollinP.E.NicholS.T.KsiazekT.G.SambharaS.RIG-I activation inhibits ebolavirus replicationVirology3922009111519628240 24ChakravarthyK.V.BonoiuA.C.DavisW.G.RanjanP.DingH.HuR.BowzardJ.B.BergeyE.J.KatzJ.M.KnightP.R.Gold"/>
  <result pre="nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1" exact="influenza" post="viral replicationProc. Natl. Acad. Sci. USA1072010101721017720498074 25JingH.SuH.C.New immunodeficiency syndromes"/>
  <result pre="macromolecule in biological realmInt. J. Biol. Macromol.118Pt A2018495629847782 29ClarkeD.K.SidhuM.S.JohnsonJ.E.UdemS.A.Rescue of" exact="mumps" post="virus from cDNAJ. Virol.7420004831483810775622 30LieberA.KiesslingU.StraussM.High level gene expression in"/>
  <result pre="in mammalian cellsGenes Dev.16200294895811959843 32LinL.LiuQ.BerubeN.DetmerS.ZhouY.5′-Triphosphate-short interfering RNA: potent inhibition of" exact="influenza" post="A virus infection by gene silencing and RIG-I activationJ."/>
  <result pre="of small hairpin RNAs targeting the NS gene of the" exact="influenza" post="A virus in cells and miceVirus Res.195201510011125192613 34JuangY.T.LowtherW.KellumM.AuW.C.LinR.HiscottJ.PithaP.M.Primary activation"/>
  <result pre="Disease Control and PreventionInfluenza antiviral medications: summary for clinicianshttps://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm2019 38BouvierN.M.LowenA.C.PaleseP.Oseltamivir-resistant" exact="influenza" post="A viruses are transmitted efficiently among guinea pigs by"/>
 </snippets>
</snippetsTree>
